Novo Nordisk confident despite Trump tariff risk as sales of weight-loss jab soar

Europe's biggest firm, whose sales of Wegovy almost doubled, feels it can meet demands' of US administration

Europe's biggest company, Novo Nordisk, has rebuffed fears of a hit to its business from Donald Trump's threatened tariffs as sales of its weight-loss drug Wegovy almost doubled.

Since the US president took office, he has imposed tariffs on Mexico and Canada - since paused for a month - and China, and has said levies of imports from the EU will definitely happen".